Red Light Therapy for Brain Health: Transcranial PBM

The idea of shining light through the skull to treat neurological conditions sounds implausible at first hearing. Yet transcranial photobiomodulation (tPBM) — the application of red or near-infrared light to the head — has become one of the most actively researched areas in photobiomodulation science. Over the past fifteen years, a growing body of clinical and preclinical evidence has demonstrated that near-infrared light can penetrate the skull, reach cortical tissue, and produce measurable neurobiological effects.

This article reviews how tPBM works, what happens when photons reach the brain, the key clinical studies to date, and practical guidance for anyone considering this approach.

How light reaches the brain through the skull

The first question most people ask is straightforward: can light actually get through bone? The answer is yes — but not all light, and not in large quantities.

The human skull is approximately 6–7 mm thick in most regions. It consists of two layers of compact bone separated by spongy bone (diploë). Visible red light (630–670 nm) penetrates poorly through this structure — studies using cadaver skulls and in-vivo measurements suggest that only 0.1–2% of surface irradiance at 630 nm reaches the outer cortical surface.

Near-infrared light (800–1100 nm) performs significantly better. At 810 nm, approximately 2–5% of surface irradiance penetrates the full thickness of the skull, depending on the skull region and individual anatomy (Tedford et al., 2015, Lasers in Surgery and Medicine). The temporal and frontal regions are thinner and allow better transmission. The occipital region is thicker and transmits less.

While 2–5% sounds small, it translates to a meaningful fluence at the cortical surface when a sufficiently powerful source is used. A device delivering 250 mW/cm² at the scalp surface would deliver approximately 5–12.5 mW/cm² to the cortex — well within the therapeutic window identified in cell culture and animal studies.

Importantly, near-infrared light also penetrates through the meninges (the protective membranes surrounding the brain) and can reach tissue 20–30 mm below the scalp surface (Jagdeo et al., 2012, Journal of Biophotonics). This means superficial cortical structures — the prefrontal cortex, motor cortex, and temporal cortex — are accessible, while deep structures like the hippocampus or brainstem are not directly reachable with current transcranial approaches.

The neurobiology of transcranial PBM

Once near-infrared photons reach neural tissue, they act through the same primary mechanism as in any other tissue: absorption by cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain.

Mitochondrial energetics

Neurons are among the most metabolically demanding cells in the body. The brain consumes approximately 20% of the body’s oxygen despite representing only 2% of body mass. This energy demand makes neurons particularly sensitive to mitochondrial dysfunction — and particularly responsive to interventions that restore mitochondrial efficiency.

When near-infrared light is absorbed by CCO, it dissociates inhibitory nitric oxide from the enzyme’s binuclear centre, restoring electron flow and increasing ATP production (Karu, 2010, Journal of Photochemistry and Photobiology B). In neurons, this translates to improved synaptic transmission, enhanced neurotransmitter synthesis, and better maintenance of ion gradients.

Neuroprotection

tPBM has demonstrated neuroprotective effects in multiple animal models. In rodent models of traumatic brain injury (TBI) and stroke, near-infrared light applied to the head within hours of injury reduces lesion volume, decreases apoptosis, and improves behavioural outcomes. The mechanisms include reduced oxidative stress, decreased pro-inflammatory cytokine expression (TNF-alpha, IL-1beta, IL-6), and upregulation of anti-apoptotic proteins such as Bcl-2 (Xuan et al., 2014, Journal of Cerebral Blood Flow and Metabolism).

Cerebral blood flow

Near-infrared light increases nitric oxide bioavailability in cerebral vasculature, promoting vasodilation and improved blood flow to irradiated brain regions. Functional near-infrared spectroscopy (fNIRS) studies in humans have confirmed that tPBM increases oxygenated haemoglobin concentrations in the prefrontal cortex during and after treatment sessions (Salgado et al., 2015, Photomedicine and Laser Surgery).

Neurogenesis and synaptogenesis

Animal studies suggest that tPBM may promote the expression of brain-derived neurotrophic factor (BDNF) and stimulate neurogenesis in the hippocampus. While these findings have not yet been confirmed in human studies, they provide a plausible mechanism for the cognitive benefits observed in some clinical trials.

Key clinical studies

Traumatic brain injury (TBI)

Naeser et al., 2011 and 2014 — Photomedicine and Laser Surgery

Margaret Naeser’s group at Boston University conducted pioneering case studies of tPBM for chronic TBI. In their 2011 publication, two patients with chronic mild TBI (years after injury) received transcranial LED treatments using 870 nm and 633 nm diodes applied to the forehead and scalp. Both patients showed improvements in cognitive function, including better sustained attention, verbal learning, and executive function, that emerged after several weeks of treatment and were maintained with continued use.

Their 2014 expanded case series (11 patients) confirmed these findings. Participants received 810 nm LED treatments three times per week for six weeks. Neuropsychological testing showed statistically significant improvements in attention, inhibition, verbal memory, and executive function. Patients also reported reductions in post-traumatic stress symptoms, sleep problems, and depressive symptoms.

These were open-label studies without a control group, which limits their evidentiary weight. However, the consistency of improvements across multiple cognitive domains and the chronic nature of the patients’ injuries (meaning spontaneous recovery was unlikely) make these findings noteworthy.

Figueiro Longo et al., 2020 — Journal of Neurotrauma

This pilot randomised controlled trial enrolled 68 patients with acute moderate TBI. The treatment group received transcranial NIR light (810 nm) within 72 hours of injury, applied for 20 minutes daily for six days. While the study was primarily a safety and feasibility trial, the treatment group showed a non-significant trend toward better cognitive outcomes at 6 months compared to the sham group.

Depression

Cassano et al., 2016 — Journal of Affective Disorders

Paolo Cassano and colleagues at Massachusetts General Hospital conducted an open-label pilot study of tPBM for major depressive disorder (MDD). Ten patients with moderate to severe depression received NIR light (810 nm, 700 mW/cm² at the device, CW mode) applied to the forehead (targeting the dorsolateral prefrontal cortex) twice per week for 8 weeks.

Hamilton Depression Rating Scale (HAM-D) scores improved significantly from a mean of 19.8 at baseline to 13 at the end of treatment. The results were encouraging, though the open-label design means placebo effects cannot be excluded.

Cassano et al., 2018 — Psychological Medicine

A follow-up study by the same group compared different treatment parameters. This was a randomised, double-blind, sham-controlled trial of 21 patients with MDD. Participants received NIR light (820 nm) to the forehead, with sessions twice per week for 8 weeks. The treatment group showed significantly greater improvement in HAM-D scores compared to sham, with a large effect size (Cohen’s d = 0.87).

Dementia and cognitive decline

Saltmarche et al., 2017 — Photomedicine and Laser Surgery

This case series examined five patients with mild to moderate dementia (including Alzheimer’s disease) treated with transcranial and intranasal PBM using 810 nm light. Treatments were administered at home by caregivers, 12 minutes per session, daily for 12 weeks. Four of five patients showed improvements on the Mini-Mental State Examination (MMSE) and the Alzheimer’s Disease Assessment Scale (ADAS-cog). Caregivers reported improved orientation, mood, and daily functioning. One patient showed no significant change.

Chao et al., 2019 — Photobiomodulation, Photomedicine, and Laser Surgery

This pilot RCT studied 8 patients with dementia who received home-based tPBM using a 810 nm LED device applied to the head for 12 weeks, followed by a 4-week washout period. The treatment group showed improvements in cognitive function (ADAS-cog), functional measures, and EEG connectivity compared to baseline. Some improvements persisted through the washout period.

Cognitive enhancement in healthy individuals

Barrett and Bhatt-Sanders, 2015 — Frontiers in Human Neuroscience

This single-blind, sham-controlled study tested whether tPBM could enhance cognitive performance in healthy adults. Participants received a single session of 1064 nm laser light applied to the right forehead. Compared to sham, the treatment group showed significantly better performance on the Wisconsin Card Sorting Test (a measure of executive function and cognitive flexibility) and the Psychomotor Vigilance Task (a measure of sustained attention and reaction time).

Blanco et al., 2017 — Cerebral Cortex

This sham-controlled study found that a single session of transcranial laser stimulation at 1064 nm to the right prefrontal cortex improved performance on a visual attention task in healthy young adults, as measured by both behavioural performance and EEG markers of sustained attention.

Conditions where tPBM is being investigated

Traumatic brain injury

The evidence is most developed here, though still preliminary. Chronic mild TBI patients appear to show the most consistent responses, possibly because their brains retain sufficient structural integrity to benefit from improved cellular energetics. Acute TBI studies are underway but results are mixed.

Major depression

The prefrontal cortex — particularly the dorsolateral prefrontal cortex (dlPFC) — is a primary target for tPBM in depression, mirroring the target used in repetitive transcranial magnetic stimulation (rTMS). Early results are promising, and several larger RCTs are currently recruiting.

Anxiety

Preliminary studies suggest tPBM may reduce anxiety symptoms, possibly through the same prefrontal cortex mechanisms as its antidepressant effects. A 2019 study by Maiello and colleagues found that a single session of tPBM reduced anxiety scores in healthy volunteers undergoing a stress challenge.

Alzheimer’s disease and dementia

The case series data is intriguing but very preliminary. The largest challenge is that Alzheimer’s disease involves deep brain structures (hippocampus, entorhinal cortex) that are beyond the reach of transcranial light. Surface cortical effects may still provide symptomatic benefit through improved neuronal energetics in accessible regions.

Parkinson’s disease

Animal models have shown neuroprotective effects of NIR light on dopaminergic neurons, and small clinical studies are exploring whether tPBM can improve motor and cognitive symptoms in Parkinson’s disease. Results to date are mixed.

Stroke recovery

The NEST (NeuroThera Effectiveness and Safety Trials) programme was a series of large multicentre trials testing transcranial NIR laser therapy for acute ischaemic stroke. NEST-1 showed a positive signal; NEST-2 failed to reach its primary endpoint but showed benefit in a pre-specified subgroup; NEST-3 was halted for futility. The failure of the NEST programme highlighted the challenges of treating deep brain tissue transcranially and the importance of patient selection and timing.

Treatment protocol

Based on published clinical studies, a reasonable protocol for general brain health and cognitive support involves the following parameters:

Wavelength: 810 nm is the most studied wavelength for transcranial applications. 850 nm is also likely effective, as it falls within the same NIR absorption window. The 1064 nm wavelength has been used in some cognitive enhancement studies but requires specialised laser equipment.

Target areas: The forehead (targeting the prefrontal cortex) is the most common application site. For broader coverage, some protocols also target the temporal regions (lateral skull), the vertex (top of head), and the occipital region (back of head).

Power density at the scalp: 100–500 mW/cm² has been used across various studies. Higher power densities compensate for skull attenuation but increase the risk of thermal effects. A reasonable starting point is 100–250 mW/cm².

Session duration: 10–20 minutes per treatment area. Total session time of 20–30 minutes if treating multiple areas sequentially.

Frequency: 3–5 times per week for therapeutic applications. Some studies used daily treatments; others used alternate-day schedules. For general cognitive support, 3 sessions per week appears sufficient.

Treatment course: Minimum 4–8 weeks to assess response. Most studies showing positive results used 6–12 week treatment courses.

Dose: The target fluence at the cortical surface is estimated at 0.5–4 J/cm². Given 2–5% transmission through the skull, this requires approximately 10–200 J/cm² at the scalp surface over the full session — well within the range delivered by standard protocols.

Devices for brain health

Purpose-built transcranial devices

Vielight Neuro Duo/Gamma/Alpha: The most widely used purpose-built tPBM device for brain health. The Neuro Duo includes transcranial LED modules positioned at specific points on the head plus an intranasal applicator. It delivers 810 nm light in either 10 Hz (Alpha) or 40 Hz (Gamma) pulsing modes. The 40 Hz Gamma frequency is of particular interest for Alzheimer’s research, as 40 Hz stimulation has been shown to reduce amyloid beta plaques in animal models (Iaccarino et al., 2016, Nature). Several clinical trials have used Vielight devices.

Intranasal devices: Standalone intranasal PBM devices deliver light to the nasal cavity, where thin tissue and rich vasculature allow NIR photons to reach nearby brain structures (the inferior frontal lobe). These are less expensive but deliver light to a limited brain region.

Using a standard red light panel

A full-body or half-body red light therapy panel with 850 nm LEDs can be used for basic transcranial applications by positioning the forehead close to the panel (10–15 cm). This provides broad coverage but less precision than purpose-built devices. Panel-based treatment is a reasonable starting point for those who already own a panel, but those seeking to maximise brain-specific effects should consider a dedicated transcranial device.

Important note: When using any device near the eyes, close your eyes and use appropriate eye protection. The panel should target the forehead, not the eyes.

Limitations and honest assessment

Transcranial PBM is one of the most exciting frontiers in photobiomodulation research, but intellectual honesty requires acknowledging the following:

1. Most studies are small. The largest positive trials have enrolled tens, not hundreds, of patients. The NEST stroke trials are the exception, and they largely failed.

2. Placebo-controlled data is limited. Many of the most cited studies are case series or open-label trials. The few sham-controlled RCTs are encouraging but small.

3. Penetration depth is a fundamental constraint. Transcranial light reaches the cortical surface but not deep brain structures. Conditions involving deep nuclei (hippocampus in Alzheimer’s, basal ganglia in Parkinson’s) may not be effectively targeted.

4. Optimal parameters are not established. Wavelength, pulsing frequency, treatment duration, power density, and number of sessions vary widely across studies. There is no consensus protocol.

5. Individual variation is high. Skull thickness, hair density, skin pigmentation, and scalp blood flow all affect how much light reaches the brain. A 6 mm skull transmits substantially more light than an 8 mm skull.

Despite these limitations, the mechanistic rationale is sound, the safety profile is excellent, and the early clinical data — particularly for chronic TBI and depression — is genuinely promising. Larger, well-designed RCTs are needed and are currently underway at several institutions worldwide.

Safety

Transcranial PBM has demonstrated an excellent safety profile across all published studies. No serious adverse events have been reported in any clinical trial. Commonly noted experiences include:

• Mild warmth at the treatment site
• Transient headache (reported by a small minority of participants)
• A feeling of relaxation or mild fatigue after treatment

There are no reports of cognitive impairment, seizures, or other neurological adverse events associated with tPBM in any published study. However, as a precaution, individuals with a history of epilepsy or photosensitive seizure disorders should consult their neurologist before using tPBM, particularly pulsed devices.

The bottom line

Transcranial photobiomodulation is a legitimate, active area of neuroscience research with a sound mechanistic basis and a growing — if still early — clinical evidence base. Near-infrared light (810 nm) can penetrate the skull in sufficient quantities to modulate cortical neuronal function. The most promising applications to date are chronic traumatic brain injury and major depression, with preliminary data also supporting potential benefits for dementia and cognitive enhancement in healthy individuals.

It is not a proven treatment for any neurological condition in the way that established medications are. But for individuals interested in emerging, non-invasive approaches to brain health, tPBM represents a safe option with genuine scientific backing — provided expectations are calibrated to the current state of the evidence.

References

• Barrett DW, Gonzalez-Lima F. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. Neuroscience. 2013;230:13–23. doi:10.1016/j.neuroscience.2012.11.016
• Blanco NJ, Maddox WT, Gonzalez-Lima F. Improving executive function using transcranial infrared laser stimulation. Journal of Neuropsychology. 2017;11(1):14–25. doi:10.1111/jnp.12074
• Cassano P, Petrie SR, Hamblin MR, et al. Review of transcranial photobiomodulation for major depressive disorder. Journal of Affective Disorders. 2016;15:268–281. doi:10.1016/j.jad.2016.06.023
• Cassano P, Petrie SR, Mischoulon D, et al. Transcranial photobiomodulation for the treatment of major depressive disorder. Psychological Medicine. 2018;48(10):1741–1751. doi:10.1017/S0033291717003506
• Chao LL. Effects of home photobiomodulation treatments on cognitive and behavioral function, cerebral perfusion, and resting-state functional connectivity in patients with dementia. Photobiomodulation, Photomedicine, and Laser Surgery. 2019;37(3):133–141.
• Iaccarino HF, Singer AC, Martorell AJ, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540(7632):230–235. doi:10.1038/nature20587
• Jagdeo JR, Adams LE, Brody NI, et al. Transcranial red and near infrared light transmission in a cadaveric model. PLoS One. 2012;7(10):e47460. doi:10.1371/journal.pone.0047460
• Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life. 2010;62(8):607–610. doi:10.1002/iub.359
• Naeser MA, Saltmarche A, Krengel MH, et al. Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury. Photomedicine and Laser Surgery. 2014;32(2):82–96. doi:10.1089/pho.2013.3564
• Saltmarche AE, Naeser MA, Ho KF, et al. Significant improvement in cognition in patients with dementia after transcranial and intranasal photobiomodulation. Photomedicine and Laser Surgery. 2017;35(8):432–441. doi:10.1089/pho.2016.4227
• Tedford CE, DeLapp S, Jacques S, et al. Quantitative analysis of transcranial and intraparenchymal light penetration in human cadaver brain tissue. Lasers in Surgery and Medicine. 2015;47(4):312–322. doi:10.1002/lsm.22343
• Xuan W, Agrawal T, Huang L, et al. Low-level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor and synaptogenesis. Journal of Biophotonics. 2015;8(6):502–511.